When immunomodulatory medicines are combined with nanocarriers that are targeted to CD44, the goal is to improve the effectiveness of immunotherapy in NSCLC, hence supporting a therapeutic plan that is unified (107). Here, CD44 is linked to non-small cell lung carcinoma.